Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344990 | 0.93 | DRD2 (0.49) | DRD2SLC6A4PRMT5OPRM1OPRL1 | |
| SCHEMBL18136608 | 0.92 | DRD2 (0.40) | DRD2SLC6A4PRMT5MCHR1OPRM1 | |
| SCHEMBL15944158 | 0.90 | PRMT5 (0.40) | DRD2SLC6A4PRMT5MCHR1IRAK4 | |
| SCHEMBL4743122 | 0.85 | DRD2 (0.44) | DRD2SLC6A4OPRM1OPRL1USP2 | |
| SCHEMBL15943820 | 0.83 | DRD2 (0.43) | DRD2SLC6A4PRMT5MCHR1OPRM1 | |
| SCHEMBL15344915 | 0.82 | DRD2 (0.50) | DRD2SLC6A4OPRM1OPRL1USP2 | |
| SCHEMBL3729078 | 0.82 | DRD2 (0.64) | DRD2SLC6A4PRMT5OPRM1OPRL1 | |
| SCHEMBL17678351 | 0.82 | GAA (0.47) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL18136684 | 0.82 | GAA (0.50) | DRD2SLC6A4OPRM1OPRL1KMT2A | |
| SCHEMBL18136723 | 0.81 | GAA (0.52) | OPRM1OPRL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777008-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-07-28 | — | — | US | disclosed |
| US-9388173-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8906900-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133427-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DRD2 4838/4885SLC6A4 4778/4885PRMT5 1/4885 |
| US-20160214985-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DRD2 4852/4885SLC6A4 4789/4885PRMT5 1/4885 |
| US-20140228343-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DRD2 4838/4885SLC6A4 4778/4885PRMT5 1/4885 |
| US-20170114061-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DRD2 4838/4885SLC6A4 4778/4885PRMT5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.